Company Information

  

Address: 405 EAGLEVIEW BOULEVARD  
City: EXTON 
State: PA 
Zip Code: 19341 
Telephone: 484-713-6000 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are an autologous cell and gene therapy company focused on translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Our approach to personalized biologics is distinctive and the foundation of our personalized biologics platform is our proprietary autologous fibroblast technology. Fibroblasts are the most common cell in skin and connective tissue and are responsible for synthesizing extracellular matrix proteins, including collagen and other growth factors, that provide structure and support. Because fibroblasts naturally reside in the localized environment of the skin and connective tissue, they represent an ideal delivery vehicle for proteins targeted to these areas. We target the underlying cause of disease by using fibroblast cells from a patient's skin to create localized therapies with genetic modification that are compatible with the unique biology of the patient (i.e., autologous).  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/2017-1.81NAN/E
06/2017-1.95NAN/E
03/2017-1.54NAN/E
12/2016-3.51NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.09Total Liab/Total Assets0.60
Net Inc/Total Assets-0.78Total Liab/Inv Cap0.71
Net Inc/Inv Cap-0.92Total Liab/Comm Equity0.07
Pretax Inc/Net Sales-43.08Interest Coverage Ratio-66.07
Net Inc/Net Sales-43.08Curr Debt/EquityNA
Cash Flow/Net Sales-82.79LTD/Equity0.22
SG&A/NetSales27.53Total Debt/Equity0.22
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio6.04
Inventory Turnover2.89Current Ratio6.04
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work Cap0.02Inv/Curr AssetsNA
Net Sales/PP&E0.24  

Income Statement (Millions)

  9/30/2017 6/30/2017 3/31/2017 12/31/2016
Total Revenues(Net Sales) 0.00 0.00 0.00 0.04
Cost of Goods Sold 0.00 0.00 0.00 0.00
Selling & Admin Exps 1.96 1.67 1.48 1.77
Operating Income -4.60 -5.03 -4.45 -4.48
Interest Exp 0.27 0.19 0.18 0.18
Pretax Income -0.12 -14.02 -5.01 -3.49
Other Income 4.75 -8.81 -0.37 1.16
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -0.12 -14.02 -5.01 -3.49

Balance Sheet (Millions)

Assets 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Cash & Short Term Investments 11.91 15.91 20.56 17.52
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA 0.00
Total Current Assets 12.18 16.35 21.12 18.03
Net Property, Plant & Equipment 1.54 1.53 1.47 1.49
Total Assets 13.78 17.97 22.69 19.58
Liabilities        
Accounts Payable 3.35 3.11 2.93 2.93
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 3.47 3.42 2.96 2.99
Long-Term Debt 1.44 1.19 2.05 1.74
Total Liabilities 17.11 21.41 12.22 11.72
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.02 0.02 0.02 0.04
Retained Earnings -181.70 -181.59 -167.57 -162.56
Treasury Stock NA NA NA NA
Total Stockholders' Equity -3.33 -3.44 10.47 7.86
Total Liabilities and Stockholders' Equity 13.78 17.97 22.69 19.58

Cash Flow Summary (Millions)

Categories 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Net Cash Provided by Operating Activities -3.90 -4.23 -4.75 -3.79
Net Cash Provided by Investing Activities -0.11 -0.16 -0.09 -0.07
Net Cash Provided by Financing Activities 0.00 -0.26 7.89 0.09

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.15-12.69--
12/20130.20-31.55--
12/20140.18-25.65--
12/20150.49-34.45--
12/20160.36-15.29-3.51
Growth Rates23.42----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17348,19555.68




Report Date : 12/11/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.